Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Run by Radiation Therapy Oncology Group · NCT01220583 · Data updated 2026-11-12
Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-12-31.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with chemotherapy or alone after surgery in treating salivary gland tumors. PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors t…
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 252 (actual) |
| Sponsor | Radiation Therapy Oncology Group Research network |
| Drugs / interventions | cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy |
| Locations | 268 sites (Canada, Saudi Arabia, United States) |
| Trial ID | NCT01220583 on ClinicalTrials.gov |
What this trial studies
OBJECTIVES: Primary Phase II * Determine the feasibility of conducting a cooperative group prospective clinical trial in patients with resected malignant salivary gland tumors. * Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin. Phase III \* Compare overall survival rates among patients receiving cisplatin and radiation to those receiving radiation alone. Secondary Phase II/III * Compare the acute toxicities of these 2 adjuvant treatments. * Compare late treatment-related adverse events in patients receiving postoperative radiation to those receiving concurrent chemoradiation. * Compare progression-free survival rates among patients receiving cisplatin and radiation to those receiving radiation alone in both the cohort of patients with pathologically high-risk disease (high-grade adenocarcinoma, high-grade mucoepidermoid carcinoma, salivary duct carcinoma), and the patient cohort with pathologically intermediate-risk disease (all other eligible diagnoses). * Investigate quality of life and patient-reported outcomes in patients enrolled in the study. * Identify the histopathology and tumor marker expression from patients enrolled on this trial and assemble a tissue bank for future correlative studies. * Establish a NRG Oncology baseline database for salivary gland malignancies to serve as a resource for future exploration of innovative and/or targeted approaches for this disease…
Who can join: the full rules
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS:
* Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes:
* Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma
* High-grade acinic cell carcinoma or high-grade (\>30% solid component) adenoid cystic carcinoma
* Surgical resection with curative intent within 8 weeks prior to registration
* All patients must have a Medical Oncology evaluation within 4 weeks prior to registration
* Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 1mm) or microscopically positive surgical margin; patients must be free of distant metastases based upon the following minimum diagnostic workup:
* History/physical examination within 8 weeks prior to registration
* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast CT imaging of the chest is required (PET/CT is acceptable)
* No patients with residual macroscopic disease after surgery
* No prior systemic chemotherapy or radiation therapy for salivary gland malignancy
PATIENT CHARACTERISTICS:
* Zubrod performance status 0-1
* Absolute neutrophil count (ANC) ≥ 1,800 cells/mm\^3
* Platelets ≥ 100,000 cells/mm\^3
* Hemoglobin ≥ 8.0 g/dL (the use of transfusion or other intervention to achieve hemoglobin ≥ 8.0 g/dL is acceptable)
* Serum creatinine \< 2.0 mg/dL
* Total bilirubin \< 2 x the institutional upper limit of normal (ULN)
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 3 x the institutional ULN
* Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
* Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment
* Not pregnant or nursing
* Patients must be deemed able to comply with the treatment plan and follow-up schedule
* Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for central review
* No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
* No severe, active co-morbidity, defined as follows:
* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
* Transmural myocardial infarction within the last 6 months
* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
* Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects (coagulation parameters are not required for entry into this protocol)
* Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition (HIV testing is not required for entry into this protocol)
* Protocol-specific requirements may also exclude immunocompromised patients
* Pre-existing ≥ grade 2 neuropathy
* No significant pre-existing hearing loss, as defined by the patient or treating physician
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior systemic chemotherapy or radiation therapy for salivary gland malignancy (prior chemotherapy for a different cancer is allowable)
* No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* No prior organ transplant
* No concurrent hematopoietic growth factors (e.g., G-CSF or pegfilgrastim) during radiotherapy
* No concurrent erythropoiesis-stimulating agents
Where it's running
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States -
The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States -
Arizona Breast Cancer Specialists-Gilbert
Gilbert, Arizona, United States -
Arizona Center for Cancer Care-Peoria
Peoria, Arizona, United States -
Cancer Center at Saint Joseph's
Phoenix, Arizona, United States -
Arizona Breast Cancer Specialists-Phoenix
Phoenix, Arizona, United States
Show 44 more locations
-
Arizona Oncology-Deer Valley Center
Phoenix, Arizona, United States -
Arizona Breast Cancer Specialists
Scottsdale, Arizona, United States -
Arizona Breast Cancer Specialists-Scottsdale
Scottsdale, Arizona, United States -
Arizona Oncology Services Foundation
Scottsdale, Arizona, United States -
Arizona Center for Cancer Care-Surprise
Surprise, Arizona, United States -
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona, United States -
Banner University Medical Center - Tucson
Tucson, Arizona, United States -
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States -
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States -
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, United States -
Mills-Peninsula Medical Center
Burlingame, California, United States -
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, United States -
Mercy San Juan Medical Center
Carmichael, California, United States -
City of Hope Comprehensive Cancer Center
Duarte, California, United States -
UC San Diego Moores Cancer Center
La Jolla, California, United States -
Los Angeles County-USC Medical Center
Los Angeles, California, United States -
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States -
Fremont - Rideout Cancer Center
Marysville, California, United States -
Memorial Medical Center
Modesto, California, United States -
Hoag Memorial Hospital
Newport Beach, California, United States -
Saint Joseph Hospital - Orange
Orange, California, United States -
Stanford Cancer Institute Palo Alto
Palo Alto, California, United States -
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, United States -
Sutter Medical Center Sacramento
Sacramento, California, United States -
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States -
UCSF Medical Center-Mount Zion
San Francisco, California, United States -
UCSF Medical Center-Mission Bay
San Francisco, California, United States -
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California, United States -
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, United States -
University of Colorado Hospital
Aurora, Colorado, United States -
Boulder Community Hospital
Boulder, Colorado, United States -
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States -
Porter Adventist Hospital
Denver, Colorado, United States -
Swedish Medical Center
Englewood, Colorado, United States -
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, United States -
Longmont United Hospital
Longmont, Colorado, United States -
McKee Medical Center
Loveland, Colorado, United States -
North Suburban Medical Center
Thornton, Colorado, United States -
Rocky Mountain Cancer Centers-Thornton
Thornton, Colorado, United States -
William Backus Hospital
Norwich, Connecticut, United States -
Helen F Graham Cancer Center
Newark, Delaware, United States -
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States -
Beebe Health Campus
Rehoboth Beach, Delaware, United States -
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
+218 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Principal investigator: Cristina P. Rodriguez, MD — OHSU Knight Cancer Institute
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.